Direct-Thrombin Inhibitor Utilization in Patients With Heparin-Induced Thrombocytopenia and Undergoing Catheter-Directed Thrombolysis: A Summary of Published Case Reports.

J Cardiovasc Nurs

Hisham A. Badreldin, PharmD, BCPS, ASH-CHC Assistant Professor of Pharmacy Practice, King Saud bin Abdulaziz University for Health Sciences, and Cardiovascular Clinical Pharmacist, King Abdulaziz Cardiac Center, King Abdulaziz Medical City, Riyadh, Saudi Arabia. Ghada Albassam, PharmD Teaching Assistant of Pharmacy Practice, King Saud bin Abdulaziz University for Health Sciences, and Pharmacist, King Abdulaziz Medical City, Riyadh, Saudi Arabia. Maha Aldoughaim, PharmD Teaching Assistant of Pharmacy Practice, King Saud bin Abdulaziz University for Health Sciences, and Pharmacist, King Abdulaziz Medical City, Riyadh, Saudi Arabia. Majed Alyami, PharmD, BCPS, ASH-CHC Assistant Professor of Pharmacy Practice, King Saud bin Abdulaziz University for Health Sciences, and Clinical Pharmacist, King Abdulaziz Medical City, Riyadh, Saudi Arabia.

Published: September 2020

Background: Catheter-directed thrombolysis (CDT) is one of the emerging venous thromboembolism management modalities. There are fairly limited data regarding the use of direct-thrombin inhibitors (DTIs) in patients with heparin-induced thrombocytopenia and undergoing CDT.

Objectives: The aim of this study was to provide a summary of the available evidence supporting the use of DTIs in patients undergoing CDT.

Methods And Results: We included 6 case reports in our analysis after searching for peer-reviewed articles and case reports in multiple research engines. Four of the 6 cases used argatroban, and 2 cases used bivalirudin. Alteplase was used in all of the 6 cases. All cases used lower activated partial thromboplastin time target. The average initial dose of alteplase ranged from 0.5 to 3 mg/h. The average duration of CDT was 26 hours (SD, 13 hours). Five patients (83%) survived after the procedure, and no complications were reported.

Conclusions: The use of DTIs might be safe and effective in selected patients with heparin-induced thrombocytopenia and undergoing CDT.

Download full-text PDF

Source
http://dx.doi.org/10.1097/JCN.0000000000000555DOI Listing

Publication Analysis

Top Keywords

patients heparin-induced
12
heparin-induced thrombocytopenia
12
thrombocytopenia undergoing
12
case reports
12
catheter-directed thrombolysis
8
dtis patients
8
patients
5
direct-thrombin inhibitor
4
inhibitor utilization
4
utilization patients
4

Similar Publications

Background: Heparin-induced thrombocytopenia (HIT) is a potentially life-threatening adverse drug reaction with numerous diagnostic challenges. Diagnosis of HIT begins with 4T score clinical assessment, followed by laboratory testing for those not deemed low risk. Laboratory testing for HIT includes screening [enzyme-linked immunosorbent assay (ELISA)] and confirmatory [serotonin release assay (SRA)] assays, wherein SRA testing can be pursued following a positive ELISA result.

View Article and Find Full Text PDF

Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction with significant thromboembolic risk. Though there are models for use of non-heparin anticoagulants, heparin remains the preferred anticoagulant in many operative settings, especially cardiovascular surgery and percutaneous cardiac intervention. The natural history of HIT can be stereotyped into phases using HIT laboratory testing to guide clinical management and determine whether heparin re-exposure can be considered.

View Article and Find Full Text PDF

Background: IgG antibodies (Abs) to platelet factor 4 complexed to heparin (PF4/H) commonly occur after heparin exposure but cause life-threatening complications of heparin-induced thrombocytopenia (HIT) in only a few patients. Presently, only platelet activation assays reliably distinguish anti-PF4/H Abs that cause disease (HIT Abs) from those likely to be asymptomatic (AAbs).

Objectives: Recent studies indicate that complement activation is an important serologic property of HIT Abs and is essential for FcγRIIA-mediated cellular activation.

View Article and Find Full Text PDF

In-Hospital and Midterm Outcomes of Lead Extraction: A Single-Center Clinical Study.

J Tehran Heart Cent

January 2024

Department of Cardiac Electrophysiology, Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.

Background: The rate of lead extraction has steadily increased alongside the extensive use of cardiovascular implantable electronic devices. Data on the complications and safety of this challenging procedure are limited. We investigated inhospital and midterm outcomes following lead extraction.

View Article and Find Full Text PDF

A 66-year-old man presented with chills, exertional dyspnea, and palpitations; he later developed a fever. Because of his elevated cardiac enzymes and electrocardiography and coronary angiography findings, he was diagnosed with acute myocarditis. Given his unstable hemodynamics, an intra-aortic balloon pump was inserted; however, he experienced a hemodynamic collapse due to refractory ventricular fibrillation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!